Aliskiren Monotherapy Does Not Cause Paradoxical Blood Pressure Rises-Reference-Cited by-同舟云学术

Aliskiren Monotherapy Does Not Cause Paradoxical Blood Pressure Rises

Published:2010-01 Issue:1 Volume:55 Page:54-60
ISSN:0194-911X
Container-title:Hypertension
language:en
Short-container-title:Hypertension

Author:

Stanton Alice V.¹,Gradman Alan H.¹,Schmieder Roland E.¹,Nussberger Juerg¹,Sarangapani Ramesh¹,Prescott Margaret F.¹

Affiliation:

1. From the Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland (A.V.S.), Dublin, Ireland; Division of Cardiovascular Diseases, Western Pennsylvania Hospital (A.H.G.), Pittsburgh, Pa; Department of Nephrology and Hypertension, University of Erlangen-Nürnberg (R.E.S.), Erlangen, Germany; Department of Medicine, Centre Hospitalier Universitaire Vaudois (J.N.), Lausanne, Switzerland; Novartis Pharmaceuticals Corporation (R.S., M.F.P.), East Hanover, N.J.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Internal Medicine

Reference20 articles.

1. Aliskiren

2. Angiotensin II Suppression in Humans by the Orally Active Renin Inhibitor Aliskiren (SPP100)

3. Renin inhibition with aliskiren: where are we now, and where are we going?

4. Plasma renin and the antihypertensive effect of the orally active renin inhibitor aliskiren in clinical hypertension

5. Aliskiren, the First Renin Inhibitor for Treating Hypertension: Reactive Renin Secretion May Limit Its Effectiveness

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical efficacy, safety and tolerability of Aliskiren Monotherapy (AM): an umbrella review of systematic reviews;BMC Cardiovascular Disorders;2020-04-17

2. Renin Inhibition with Aliskiren: A Decade of Clinical Experience;Journal of Clinical Medicine;2017-06-09

3. Management of Hypertension-Journey from Single Drug Therapy to Multitargeted Ligand Therapy: A Clinical Overview;Current Clinical Pharmacology;2015-10-28

4. State of the art paper Aliskiren – an alternative to angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in the therapy of arterial hypertension;Archives of Medical Science;2014

5. Direct renin inhibition: extricating facts from façades;Therapeutic Advances in Cardiovascular Disease;2013-03-13